CN1625414A - 药物组合物 - Google Patents
药物组合物 Download PDFInfo
- Publication number
- CN1625414A CN1625414A CNA038031442A CN03803144A CN1625414A CN 1625414 A CN1625414 A CN 1625414A CN A038031442 A CNA038031442 A CN A038031442A CN 03803144 A CN03803144 A CN 03803144A CN 1625414 A CN1625414 A CN 1625414A
- Authority
- CN
- China
- Prior art keywords
- propofol
- pharmaceutical composition
- cyclodextrin
- solution
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Anesthesiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA2002/0929 | 2002-02-01 | ||
| ZA200200929 | 2002-02-01 | ||
| US40163302P | 2002-08-06 | 2002-08-06 | |
| US60/401,633 | 2002-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1625414A true CN1625414A (zh) | 2005-06-08 |
Family
ID=27669352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA038031442A Pending CN1625414A (zh) | 2002-02-01 | 2003-01-29 | 药物组合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20050239746A1 (enExample) |
| EP (1) | EP1469886B8 (enExample) |
| JP (1) | JP2005522422A (enExample) |
| CN (1) | CN1625414A (enExample) |
| AT (1) | ATE326985T1 (enExample) |
| AU (1) | AU2003205930B2 (enExample) |
| BR (1) | BR0307518A (enExample) |
| CA (1) | CA2474710A1 (enExample) |
| DE (1) | DE60305438T2 (enExample) |
| MX (1) | MXPA04007328A (enExample) |
| NZ (1) | NZ534598A (enExample) |
| WO (1) | WO2003063824A2 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101287447B (zh) * | 2005-08-12 | 2012-10-24 | 印度血清及疫苗有限公司 | 包含丙泊酚的水性麻醉剂组合物 |
| CN103172658A (zh) * | 2011-12-26 | 2013-06-26 | 宜昌人福药业有限责任公司 | 一种适合药用的前体药物晶型、制备方法及药用组合物 |
| CN103491953A (zh) * | 2011-02-04 | 2014-01-01 | 诺伯特·勒韦尔 | 药物制剂 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004025151D1 (de) * | 2004-03-10 | 2010-03-04 | Shimoda Biotech Pty Ltd | Stabile injizierbare Diclofenac- Zubereitungen |
| US20060198891A1 (en) | 2004-11-29 | 2006-09-07 | Francois Ravenelle | Solid formulations of liquid biologically active agents |
| CN101155580A (zh) | 2005-04-13 | 2008-04-02 | 株式会社大塚制药工场 | 含异丙酚的脂肪乳剂 |
| EP2522343A1 (en) | 2006-03-28 | 2012-11-14 | Javelin Pharmaceuticals, Inc. | Formulations of Low Dose Diclofenac and Beta-Cyclodextrin |
| EP2106786A1 (de) * | 2008-04-04 | 2009-10-07 | Roewer, Norbert, Univ.-Prof. Dr. med. | Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin |
| ES2784629T3 (es) * | 2011-11-29 | 2020-09-29 | Jurox Pty Ltd | Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona |
| US9925274B2 (en) | 2012-11-15 | 2018-03-27 | Sapiotec Gmbh | Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient |
| JP6234475B2 (ja) | 2012-12-11 | 2017-11-22 | ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＳＡＰＩＯＴＥＣ ＧｍｂＨ | メラノーマ細胞に対抗するためのデルフィニジン |
| EP2913050A1 (de) * | 2014-02-28 | 2015-09-02 | SapioTec GmbH | Verfahren zur Herstellung eines Flurankomplexes |
| CN104523591B (zh) * | 2014-12-19 | 2019-01-18 | 西安力邦肇新生物科技有限公司 | 无致敏性、无痛丙泊酚脂肪微乳冻干制剂配方和制备方法 |
| CN111529695A (zh) * | 2020-04-30 | 2020-08-14 | 首都医科大学附属北京康复医院（北京工人疗养院） | 一种环糊精可溶性ace2及其制备方法和应用 |
| KR102975307B1 (ko) * | 2020-10-30 | 2026-06-10 | 현대자동차주식회사 | 차아염소산수를 이용한 차량용 살균장치 및 그 제어방법 |
| FR3117337B1 (fr) | 2020-12-10 | 2023-04-28 | Centre Hospitalier Univ De Lille | Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable |
| CN118715017A (zh) * | 2022-02-18 | 2024-09-27 | 贝伦治疗公益公司 | 用2-羟基丙基-β-环糊精治疗高甘油三酯血症 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA828580B (en) * | 1981-12-23 | 1983-10-26 | Schering Corp | Interferon formulations |
| ZA962214B (en) * | 1995-04-10 | 1996-10-07 | Farmarc Nederland Bv | Pharmaceutical composition |
| AU5774796A (en) * | 1995-06-13 | 1997-01-09 | Dyer, Alison Margaret | Pharmaceutical compositions containing lornoxicam and cyclod extrin |
| DE69721235T2 (de) * | 1996-02-19 | 2004-02-05 | Amersham Health As | Verbesserungen an (oder im bezug auf) kontrastmittel |
| US6407278B2 (en) * | 1998-11-16 | 2002-06-18 | Medimmune Oncology, Inc. | Stable amorphous amifostine compositions and methods for the preparation and use of the same |
| US6440414B1 (en) * | 1999-10-01 | 2002-08-27 | Amgen Inc. | Pharmaceutical compositions of fibrinolytic agent |
| DE60017194T2 (de) * | 1999-10-29 | 2005-12-22 | Merck & Co., Inc. | Verfahren zur herstellung von carbapenem-antibiotika zubereitungen |
| IN187686B (enExample) * | 2000-06-21 | 2002-06-08 | Bharat Serums & Vaccines Ltd | |
| EP1383445A4 (en) * | 2001-03-20 | 2005-04-13 | Cydex Inc | FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN |
-
2003
- 2003-01-29 WO PCT/IB2003/000266 patent/WO2003063824A2/en not_active Ceased
- 2003-01-29 US US10/503,067 patent/US20050239746A1/en not_active Abandoned
- 2003-01-29 MX MXPA04007328A patent/MXPA04007328A/es unknown
- 2003-01-29 JP JP2003563518A patent/JP2005522422A/ja active Pending
- 2003-01-29 AT AT03702813T patent/ATE326985T1/de not_active IP Right Cessation
- 2003-01-29 NZ NZ534598A patent/NZ534598A/en not_active IP Right Cessation
- 2003-01-29 BR BR0307518-4A patent/BR0307518A/pt not_active IP Right Cessation
- 2003-01-29 CA CA002474710A patent/CA2474710A1/en not_active Abandoned
- 2003-01-29 AU AU2003205930A patent/AU2003205930B2/en not_active Ceased
- 2003-01-29 DE DE60305438T patent/DE60305438T2/de not_active Expired - Lifetime
- 2003-01-29 EP EP03702813A patent/EP1469886B8/en not_active Expired - Lifetime
- 2003-01-29 CN CNA038031442A patent/CN1625414A/zh active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101287447B (zh) * | 2005-08-12 | 2012-10-24 | 印度血清及疫苗有限公司 | 包含丙泊酚的水性麻醉剂组合物 |
| CN103491953A (zh) * | 2011-02-04 | 2014-01-01 | 诺伯特·勒韦尔 | 药物制剂 |
| CN103172658A (zh) * | 2011-12-26 | 2013-06-26 | 宜昌人福药业有限责任公司 | 一种适合药用的前体药物晶型、制备方法及药用组合物 |
| CN103172658B (zh) * | 2011-12-26 | 2016-01-20 | 宜昌人福药业有限责任公司 | 一种适合药用的前体药物晶型、制备方法及药用组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04007328A (es) | 2005-07-05 |
| WO2003063824A3 (en) | 2004-06-17 |
| WO2003063824A2 (en) | 2003-08-07 |
| DE60305438T2 (de) | 2006-12-21 |
| NZ534598A (en) | 2004-11-26 |
| CA2474710A1 (en) | 2003-08-07 |
| ATE326985T1 (de) | 2006-06-15 |
| AU2003205930B2 (en) | 2007-08-16 |
| EP1469886B8 (en) | 2008-01-09 |
| DE60305438D1 (de) | 2006-06-29 |
| BR0307518A (pt) | 2004-12-28 |
| EP1469886A2 (en) | 2004-10-27 |
| EP1469886B1 (en) | 2006-05-24 |
| US20050239746A1 (en) | 2005-10-27 |
| JP2005522422A (ja) | 2005-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7678776B2 (en) | Inclusion complexes of butylphthalide with cyclodextrin or its derivatives, a process for their preparation and the use thereof | |
| EP1469886B1 (en) | Lyophilized pharmaceutical composition of propofol | |
| US9549994B2 (en) | Compositions of nicardipine and sulfoalkylated β-cyclodextrin | |
| KR100349754B1 (ko) | 제약조성물 | |
| EP2349340B1 (en) | Stable aqueous formulations of water insoluble or poorly soluble drugs | |
| AU2003205930A1 (en) | Pharmaceutical composition | |
| CN1492760A (zh) | 环糊精制剂 | |
| CN103228296B (zh) | 苯达莫司汀阴离子-阳离子型环聚糖组合物 | |
| WO2005082419A1 (en) | Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration | |
| EP2035040B1 (en) | Pharmaceutical composition for administration by injection | |
| KR20040091004A (ko) | 약제학적 조성물 | |
| CN1177583C (zh) | 具有改进药理学性质的非肠胃道使用的雌莫司汀磷酸盐制剂 | |
| ZA200406021B (en) | Pharmaceutical composition | |
| CN1868471A (zh) | 一种甲基斑蝥胺注射制剂及其制备方法 | |
| HK1064056B (en) | An aqueous pharmaceutical preparation of cilostazol for parenteral use | |
| HK1064056A1 (en) | An aqueous pharmaceutical preparation of cilostazol for parenteral use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |